4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Non-Current Deffered Revenue data on file, last reported at $2.1 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $2.1 million, up 389.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (up 389.63% YoY), and the FY2025 annual result was $745000.0, down 29.52% from the prior year.
• Non-Current Deffered Revenue improved to $2.1 million in Q1 2026 per FDMT's latest filing, from $745000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $2.1 million in Q1 2026 and troughed at $219000.0 in Q2 2025.
• A 5-year average of $1.1 million and a median of $1.1 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2026: Non-Current Deffered Revenue plunged 84.94% in 2022, then surged 389.63% in 2026.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $1.1 million in 2022, then slipped by 9.67% to $972000.0 in 2023, then increased by 8.74% to $1.1 million in 2024, then declined by 29.52% to $745000.0 in 2025, then soared by 185.23% to $2.1 million in 2026.
• Business Quant data shows FDMT's Non-Current Deffered Revenue at $2.1 million in Q1 2026, $745000.0 in Q4 2025, and $835000.0 in Q3 2025.